Variables | Group 1 (Pre-2008) | Group 2 (Post-2008) | P-values between Group 1 and Group 2 | |||||
---|---|---|---|---|---|---|---|---|
Unilateral (N = 51) | Bilateral (N = 50) | P-value | Unilateral (N = 118) | Bilateral (N = 72) | P-value | Unilat I vs II | Bilat I vs II | |
Coa (μg/L) | 1.7 ± 1.90 | 3.1 ± 2.32 | 0.0013b | 1.3 ± 0.93 | 2.2 ± 1.33 | <0.0001b | 0.0679 | 0.0076b |
Cra (μg/L) | 1.6 ± 2.15 | 2.5 ± 2.04 | 0.0235b | 1.2 ± 1.10 | 1.9 ± 1.67 | 0.0006b | 0.1107 | 0.0775 |
Follow-Up Date (Yrs) | 5.4 ± 1.93 | 6.5 ± 2.24 | 0.0095b | 2.2 ± 1.14 | 2.5 ± 1.16 | 0.0821 | <0.0001b | <0.0001b |
#, % Patients Tested | 105 (87 %) | -- | 187 (77 %) | -- | 0.0316b | |||
#, % Levels Converted | 17 (33 %) | 21 (42 %) | 0.3320 | 26 (22 %) | 19 (25 %) | 0.5961 | 0.1416 | 0.0510 |
#, % Revised (Excluded) | 15 (12 %) | 6 (5 %) | 0.0394b | 2 (0.8 %) | 0 (0 %) | 0.1556 | <0.0001b | 0.0005b |
#, % Revised AWRF (Excluded) | 2 (1.7 %) | 2 (1.7 %) | 1.000 | 0 (0 %) | 0 (0 %) | 1.000 | 0.0444b | 0.0444b |
Normal (#, %) | 32 (56 %) | 6 (12.5 %) | <0.0001b | 86 (77 %) | 20 (28 %) | <0.0001b | 0.0058b | 0.0466b |
Optimal (#, %) | 49 (86 %) | 35 (73 %) | 0.0949 | 111 (99 %) | 63 (88 %) | 0.0007b | 0.0003b | 0.0434b |
Acceptable (#,%) | 7 (12.3 %) | 12 (25 %) | 0.0910 | 3 (2.7 %) | 9 (12.5 %) | 0.0085b | 0.0124b | 0.0767 |
Problematic (#, %) | 1 (1.8 %) | 1 (2.1 %) | 0.9045 | 0 (0 %) | 0 (0 %) | 1.000 | 0.1585 | 0.2187 |
Potentially Toxic (#, %) | 0 (0 %) | 0 (0 %) | 1.000 | 0 (0 %) | 0 (0 %) | 1.000 | 1.000 | 1.000 |